Intrommune Therapeutics' Phase 1 OMEGA study demonstrates successful safety profile of innovative toothpaste-based peanut allergy treatment, with all participants tolerating their highest assigned dose.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.